There are very few versions of either Chloroquine or Proguanil on the market in most countries despite being a reasonable market size and in view of this Beacon has developed -

1. 250 mg chloroquine phosphate tablets x 20
2. 100 mg proguanil hydrochloride tablets x 98
3. A combination pack of 100 mg proguanil hydrochloride tablets x 98 plus 250 mg chloroquine phosphate tablets x 14

Regulatory SituationA CTD dossier for each of the above three products is due to be completed by February 2009 and will be submitted under a DCP in the EU with the UK MHRA as RMS. Licensees for EU territories will either be able to join the DCP with their territory as a CMS or apply directly.In the UK the malaria indications of the above products are regarded as Pharmacy (P) products than being categorised as Prescription Only Medicines (POM). This situation may vary from territory to territory.

Licensing Situation

Beacon is looking for a licensing partners throughout the EU, North America, South America and Asia that can demonstrate that they are well situated to market the above products as brands and to maximise the market opportunity.

Information Required

Any company that is interested in a licensing opportunity should contact Beacon to express an interest and provide the following information:

1. Territory.
2. Details of company, product portfolio and organisation.
3. Market review of Chloroquine and Proguanil in territory including details of competitors, prices, and sales.
4. Regulatory situation.
5. Proposed marketing activity.
6. Forecast.